Fall 2026

Operations Co-op

Updated on 8/17/2026

Deadline 8/25/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

No H1B Sponsorship

Athens, GA, USA

In Person

Bachelor's, Master's, MBA

Category
Operations & Logistics (1)
Required Skills
Process Engineering
GMP
FDA Regulations
Risk Management
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Permanently authorized to work in the United States and not require employment visa sponsorship, including H-1B or green-card sponsorship, currently or in the future.
  • Be actively enrolled in an accredited university for the duration of the co-op.
  • Currently pursue a Bachelor's, Master's, or Master of Business Administration program in Chemical Engineering, Biomedical Engineering, or a related engineering discipline.
  • Have completed the freshman year of an undergraduate program at an accredited university.
  • Maintain a minimum GPA of 2.8.
  • Demonstrate strong analytical and quantitative skills.
  • Balance multiple projects and initiatives while executing results.
  • Work independently while contributing to team goals.
  • Read, analyze, and interpret complex scientific and technical journals.
  • Write effectively to communicate prepared work and explain conclusions and recommendations.
  • Apply advanced mathematical concepts including exponents, logarithms, quadratic equations, and permutations.
  • Apply mathematical operations including frequency distribution, test reliability and validity, analysis of variance, correlation techniques, sampling theory, and factor analysis.
  • Interpret instructions provided in written, oral, diagram, or schedule form.
  • Define problems, collect data or information, establish facts, and draw valid conclusions.
  • Meet the physical requirements of the role, including talking, hearing, standing, walking, sitting, using hands, reaching, and moving around the plant for on-site observations.
  • Successfully complete regulatory and job training requirements.
Responsibilities
  • Provide technical support for assigned functions and processes.
  • Perform analysis to measure process performance and implement improvements in process cycle time, yield, and quality to improve operational efficiency.
  • Support the introduction and validation of new and existing products.
  • Provide guidance for new equipment design, installation, and qualification under the supervision and mentorship of process engineers, manufacturing process specialists, or management.
  • Acquire skills to provide day-to-day support for assigned processes.
  • Maintain, update, and author production, safety, and regulatory documentation, including operating instructions, batch production records, criticality analyses, piping and instrumentation diagrams, key and controlled parameter documents, deviations, and corrective action plans.
  • Participate in problem-solving efforts by analyzing and correcting process and equipment problems.
  • Implement process surveillance programs under supervision, focusing on process control, yields, cycle times, quality, and changeover; prepare written interpretations of plant operating data and implement corrective action.
  • Support coordination of small engineering projects.
  • Prepare reports informing leadership of work in progress and expected completion dates.
  • Conduct or participate in laboratory, pilot-plant, or plant-scale development investigations to improve procedures, equipment, or processes for existing products.
  • Document and execute process and cleaning validation for new and existing products.
  • Support and facilitate new-process introduction by coordinating and executing preparation activities for process start-ups and providing technical coverage.
  • Assist with new and existing process and equipment design.
  • Execute cost-reduction and efficiency-improvement projects using Process or Design Excellence techniques and risk-management tools such as FMEA, HAZOP, LOPA, and business-risk evaluations.
  • Maintain knowledge of current good manufacturing practices, process safety practices, and environmental standards.
  • Support investigations and root-cause analyses for nonconformances, documenting findings and corrective actions in the quality management system.
  • Assist as a Synthesis Specialist or system/equipment owner.
  • Deliver accurate, high-quality work on schedule to meet production requirements.
  • Participate in plant safety programs, including Process Hazard Analyses, for new and existing processes.
  • Execute duties in compliance with state and federal regulations and guidelines, including FDA, EPA, OSHA, and DEA requirements.
  • Participate in other projects or assignments requested by management.
  • Perform on-site observations throughout the plant.
Desired Qualifications
  • Demonstrate excellent communication, presentation, and leadership skills.
  • Demonstrate leadership or participation in campus programs and/or community service activities.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.